Arvinas unveils preclinical findings for ARV-806
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 24 2025
0mins
Should l Buy ARVN?
ARV-806 Overview: Arvinas presented preclinical data for ARV-806, a PROTAC KRAS G12D degrader, at the 2025 AACR-NCI-EORTC conference, highlighting its potential to target both ON and OFF forms of the KRAS G12D mutation, which is prevalent in various solid tumors.
Efficacy and Potency: The data showed that ARV-806 effectively degraded KRAS G12D with high potency in cancer cell lines and demonstrated significant tumor volume reductions in preclinical models, indicating its potential as a best-in-class therapy for KRAS G12D mutated cancers.
Clinical Development: Arvinas is currently conducting a Phase 1 clinical trial for ARV-806 in patients with advanced solid tumors harboring the KRAS G12D mutation, aiming to address the unmet medical needs in this area.
Pharmacodynamic Activity: ARV-806 exhibited sustained pharmacodynamic activity, maintaining target degradation for over a week, which supports the possibility of intermittent dosing in clinical settings.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ARVN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ARVN
Wall Street analysts forecast ARVN stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 10.100
Low
15.00
Averages
16.00
High
18.00
Current: 10.100
Low
15.00
Averages
16.00
High
18.00
About ARVN
Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Insider Buying by Waters and Arvinas Directors
- Waters Insider Purchase: Waters' Director Richard H. Fearon bought 1,000 shares at $306.34 each for a total of $306,340, marking his first purchase in the past year, indicating confidence in the company's future.
- Market Opportunity: Waters shares traded as low as $295.02 on Wednesday, 3.7% below Fearon's purchase price, presenting a relatively low entry point for investors, despite the stock being down about 1.2% on the day.
- Arvinas Insider Purchase: Arvinas' Director Briggs Morrison purchased 20,000 shares at $13.40 each for a total investment of $268,070, reflecting his positive outlook on the company's prospects.
- Historical Purchase Comparison: Prior to this purchase, Morrison had bought 227,010 shares at $7.57 each in the past year, demonstrating his sustained confidence in Arvinas, even as the stock fell approximately 3.2% on Wednesday.
See More
Arvinas, Inc. Q4 2025 Earnings Call Insights
- New Drug Application Milestone: Arvinas is submitting its first new drug application, potentially leading to the first-ever FDA approval of a PROTAC degrader, marking the company’s entry into a period with multiple value-driving milestones that could boost stock prices and enhance market confidence.
- Clinical Trial Progress: The company is focusing resources on four Phase I clinical programs, including ARV-102 and ARV-806, with plans to share new clinical data in 2026, indicating strong anticipation for future data readouts that may bolster investor confidence in long-term growth.
- Strong Financial Position: As of the fourth quarter, Arvinas reported over $685 million in cash and cash equivalents, although down from over $1 billion at the end of 2024, it maintains guidance for cash runway into the second half of 2028, ensuring continued investment capability.
- Effective Cost Control: General and administrative expenses for the fourth quarter were $23 million, significantly down from $34.1 million in the prior year, reflecting effective cost control measures in personnel and infrastructure, further enhancing financial flexibility.
See More
Arvinas Reports Q4 Earnings Miss with Significant Revenue Decline
- Earnings Miss: Arvinas reported a Q4 GAAP EPS of -$1.10, missing expectations by $0.62, indicating significant challenges in profitability for the company.
- Revenue Decline: The company generated $9.5 million in revenue, an 84% year-over-year decrease, falling short of the expected $27.76 million, reflecting weak market demand and insufficient sales strategies.
- Cash Flow Outlook: Arvinas believes that its cash, cash equivalents, and marketable securities as of December 31, 2025, will be sufficient to fund planned operating expenses and capital expenditures into the second half of 2028, indicating a degree of financial stability.
- Leadership Transition: The appointment of a new president and CEO has been announced, and this leadership change may impact the company's strategic direction and future development.
See More
Arvinas Scheduled to Announce Q4 Earnings on February 24
- Earnings Announcement Schedule: Arvinas is set to release its Q4 earnings on February 24 before market open, with a consensus EPS estimate of -$0.57, reflecting a 9.5% year-over-year decline, indicating challenges in profitability.
- Revenue Decline Forecast: The anticipated revenue for Q4 is $37.26 million, representing a 37.1% year-over-year decrease, which highlights pressures on the company from market competition and product sales, potentially impacting investor confidence.
- Earnings Estimate Adjustments: Over the past three months, EPS estimates have seen no upward revisions and one downward revision, suggesting a weakening analyst confidence in the company's future performance, which may lead to stock price volatility.
- Leadership Transition: Arvinas has announced the appointment of a new president and CEO, and this leadership change could influence the company's strategic direction and market performance, prompting investors to monitor the new leadership's policies and execution capabilities.
See More
Arvinas Appoints New CEO Randy Teel Amid 11% Stock Drop
- CEO Appointment Context: Arvinas appointed Randy Teel as CEO after a comprehensive search, succeeding John Houston, which led to an 11% drop in stock price on Thursday, indicating market concerns over the leadership change.
- Leadership Experience: Teel, previously the Chief Business Officer, played a crucial role in the company's 2018 IPO, bringing extensive industry experience that is expected to positively impact the company's clinical-stage biotechnology development.
- Strategic Direction Shift: Teel stated that the company will focus on earlier-stage clinical programs, aiming to leverage the PROTAC degrader platform to transform treatment paradigms for serious diseases, a strategic shift that could influence future R&D directions and market positioning.
- Market Reaction: Despite the stock drop, sentiment on Stocktwits for ARVN shifted from 'neutral' to 'bullish', with some users viewing the decline as an overreaction, reflecting confidence in the new CEO's capabilities.
See More
Arvinas Appoints New CEO and Board Chair
- Executive Changes: Arvinas has appointed Randy Teel as the new CEO and president, effective immediately, with Teel previously serving as the chief business officer, where he played a crucial role in driving corporate growth and industry partnerships, indicating a strategic focus on continued development.
- Board Restructuring: Teel will also serve as a board member, succeeding the retiring John Houston, who will remain on the board and provide consulting services, ensuring stability and continuity during this transition period for the company.
- New Board Chair: Briggs Morrison has been elected as the new chair of the board, effective immediately, with this leadership change aimed at strengthening corporate governance and enhancing decision-making efficiency to address industry challenges.
- Market Reaction: Although Arvinas' assets are viewed as mediocre, the market shows cautious optimism regarding the new executive appointments, which may influence the company's future stock performance.
See More
Insider Buying by Waters and Arvinas Directors
- Waters Insider Purchase: Waters' Director Richard H. Fearon bought 1,000 shares at $306.34 each for a total of $306,340, marking his first purchase in the past year, indicating confidence in the company's future.
- Market Opportunity: Waters shares traded as low as $295.02 on Wednesday, 3.7% below Fearon's purchase price, presenting a relatively low entry point for investors, despite the stock being down about 1.2% on the day.
- Arvinas Insider Purchase: Arvinas' Director Briggs Morrison purchased 20,000 shares at $13.40 each for a total investment of $268,070, reflecting his positive outlook on the company's prospects.
- Historical Purchase Comparison: Prior to this purchase, Morrison had bought 227,010 shares at $7.57 each in the past year, demonstrating his sustained confidence in Arvinas, even as the stock fell approximately 3.2% on Wednesday.
See More
Arvinas, Inc. Q4 2025 Earnings Call Insights
- New Drug Application Milestone: Arvinas is submitting its first new drug application, potentially leading to the first-ever FDA approval of a PROTAC degrader, marking the company’s entry into a period with multiple value-driving milestones that could boost stock prices and enhance market confidence.
- Clinical Trial Progress: The company is focusing resources on four Phase I clinical programs, including ARV-102 and ARV-806, with plans to share new clinical data in 2026, indicating strong anticipation for future data readouts that may bolster investor confidence in long-term growth.
- Strong Financial Position: As of the fourth quarter, Arvinas reported over $685 million in cash and cash equivalents, although down from over $1 billion at the end of 2024, it maintains guidance for cash runway into the second half of 2028, ensuring continued investment capability.
- Effective Cost Control: General and administrative expenses for the fourth quarter were $23 million, significantly down from $34.1 million in the prior year, reflecting effective cost control measures in personnel and infrastructure, further enhancing financial flexibility.
See More
Arvinas Reports Q4 Earnings Miss with Significant Revenue Decline
- Earnings Miss: Arvinas reported a Q4 GAAP EPS of -$1.10, missing expectations by $0.62, indicating significant challenges in profitability for the company.
- Revenue Decline: The company generated $9.5 million in revenue, an 84% year-over-year decrease, falling short of the expected $27.76 million, reflecting weak market demand and insufficient sales strategies.
- Cash Flow Outlook: Arvinas believes that its cash, cash equivalents, and marketable securities as of December 31, 2025, will be sufficient to fund planned operating expenses and capital expenditures into the second half of 2028, indicating a degree of financial stability.
- Leadership Transition: The appointment of a new president and CEO has been announced, and this leadership change may impact the company's strategic direction and future development.
See More
Arvinas Scheduled to Announce Q4 Earnings on February 24
- Earnings Announcement Schedule: Arvinas is set to release its Q4 earnings on February 24 before market open, with a consensus EPS estimate of -$0.57, reflecting a 9.5% year-over-year decline, indicating challenges in profitability.
- Revenue Decline Forecast: The anticipated revenue for Q4 is $37.26 million, representing a 37.1% year-over-year decrease, which highlights pressures on the company from market competition and product sales, potentially impacting investor confidence.
- Earnings Estimate Adjustments: Over the past three months, EPS estimates have seen no upward revisions and one downward revision, suggesting a weakening analyst confidence in the company's future performance, which may lead to stock price volatility.
- Leadership Transition: Arvinas has announced the appointment of a new president and CEO, and this leadership change could influence the company's strategic direction and market performance, prompting investors to monitor the new leadership's policies and execution capabilities.
See More
Arvinas Appoints New CEO Randy Teel Amid 11% Stock Drop
- CEO Appointment Context: Arvinas appointed Randy Teel as CEO after a comprehensive search, succeeding John Houston, which led to an 11% drop in stock price on Thursday, indicating market concerns over the leadership change.
- Leadership Experience: Teel, previously the Chief Business Officer, played a crucial role in the company's 2018 IPO, bringing extensive industry experience that is expected to positively impact the company's clinical-stage biotechnology development.
- Strategic Direction Shift: Teel stated that the company will focus on earlier-stage clinical programs, aiming to leverage the PROTAC degrader platform to transform treatment paradigms for serious diseases, a strategic shift that could influence future R&D directions and market positioning.
- Market Reaction: Despite the stock drop, sentiment on Stocktwits for ARVN shifted from 'neutral' to 'bullish', with some users viewing the decline as an overreaction, reflecting confidence in the new CEO's capabilities.
See More
Arvinas Appoints New CEO and Board Chair
- Executive Changes: Arvinas has appointed Randy Teel as the new CEO and president, effective immediately, with Teel previously serving as the chief business officer, where he played a crucial role in driving corporate growth and industry partnerships, indicating a strategic focus on continued development.
- Board Restructuring: Teel will also serve as a board member, succeeding the retiring John Houston, who will remain on the board and provide consulting services, ensuring stability and continuity during this transition period for the company.
- New Board Chair: Briggs Morrison has been elected as the new chair of the board, effective immediately, with this leadership change aimed at strengthening corporate governance and enhancing decision-making efficiency to address industry challenges.
- Market Reaction: Although Arvinas' assets are viewed as mediocre, the market shows cautious optimism regarding the new executive appointments, which may influence the company's future stock performance.
See More
